Related Experiment Video
Updated: Jul 10, 2025
13:46
An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons
Published on: July 11, 2020
5.8K
Challenges in recombinant brain-derived neurotrophic factor production.
Éllen F Rodrigues1, Ana L Fachin2, Mozart Marins3
1Biotechnology Unit, University of Ribeirão Preto/UNAERP, Ribeirão Preto, SP, Brazil.
Trends in Biotechnology
|November 26, 2023
Summary
Producing bioactive brain-derived neurotrophic factor (BDNF) for pharmaceuticals is challenging due to its structural integrity. Efficient industrial production requires a carefully selected expression system to ensure stability and efficacy.
Area of Science:
- Neuroscience
- Biotechnology
- Pharmaceutical Sciences
Background:
- Brain-derived neurotrophic factor (BDNF) is a crucial neurotrophin with significant commercial and therapeutic potential.
- Maintaining the structural integrity, specifically the cystine-knot, of BDNF presents a major hurdle in its large-scale production.
Purpose of the Study:
- To highlight the importance of expression systems in the industrial production of BDNF.
- To address the challenge of producing stable and bioactive BDNF for pharmaceutical applications.
Main Methods:
- This study focuses on the critical role of expression systems in overcoming production challenges.
- It emphasizes the need for systems that preserve the structural integrity of BDNF.
Main Results:
- The selection of an appropriate expression system is paramount for efficient BDNF production.
- Successful production hinges on maintaining the neurotrophin's bioactive and stable form.
Conclusions:
- A suitable expression system is essential for the industrial-scale manufacturing of pharmaceutical-grade BDNF.
- Addressing the structural preservation challenges will enable the therapeutic use of BDNF.
